Conduit Pharmaceuticals Bolsa (NASDAQ: CDT)

Últimas noticias sobre Conduit Pharmaceuticals (NASDAQ:CDT) Bolsa

Conduit Pharmaceuticals

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ACTG

ALUR

BTAI

CNTA

DALN

DWTX

EVAX

FFBC

HYZN

LITM

MLYS

NVNI

PBBK

SEPN

STBX

TRUG

TWLO

Twilio sube un 18,5% tras superar expectativas de ingresos. Explora los movimientos clave del mercado previo de hoy.

Acciones de Twilio (TWLO) se disparan más de un 18%; 20 acciones que se mueven en el premercado de EE.UU.

AMPG

AREB

BHAT

BWMN

CALM

DATS

DRIO

EONR

GRFX

HOTH

JBDI

LAES

RGTI

RIME

SANA

SLDB

SVMH

XTIA

Movimientos destacados del premercado: Cal-Maine Foods sube un 3,8%, Sana Biotechnology lidera con un 220,6%.

Las acciones de Cal-Maine Foods suben un 4%; Aquí están 20 acciones que se mueven en el premercado

Conduit Pharmaceuticals Inc. - Common Stock

Conduit Pharmaceuticals Inc

Infinitii Ai Inc

CDT Environmental Technology Investment Holdings Limited - ordinary shares

CDT Environmental Technology Investment Holdings Ltd

CDTI ADVANCED MATERIALS by CDTI Advanced Materials, Inc.

CDTi Advanced Materials Inc

Cidara Therapeutics Inc

Earnings

Niu Technologies Q1 Adj. EPADS $(0.05) Up From $(0.10) YoY, Sales $93.98M Up From $69.91M YoY

Willy Woo, a widely followed Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) influencer and analyst, revealed the series of events Sunday that caused them to close a business that was making him &#8220;millions per year.&#8221;
What Happened:&nbsp;In an X thread, Woo shared the journey about The Bitcoin Forecast, a subscription-based content offering on Substack that analyzed BTC&#8217;s on-chain signals and predicted the future course of the market.
The Bitcoin Forecast, which started in October 2020, quickly gained traction, according to Woo, prompting them to get BTC payments integrated for subscriptions.
&#8220;By 6 months I had almost 10,000 paid subs. I&#8217;m pretty sure even today it&#8217;s the most successful BTC investment letter to date,&#8221; Woo said. 
Benzinga couldn&#8217;t independently verify these claims. Substack didn&#8217;t immediately return a request for comment.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Exactly 3 years ago I shut down a business making me millions per year. Here&#39;s a &#x1f9f5;on how it started, why I shut it down and why I&#39;m helping to build something better for this industry.
&mdash; Willy Woo (@woonomic) <a href="https://twitter.com/woonomic/status/1924227623074554195?ref_src=twsrc%5Etfw">May 18, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also:<a href="https://www.benzinga.com/25/04/44621245/gold-backed-cryptos-match-yellow-metals-highs-following-trumps-liberation-day-shock"> </a><a href="https://www.benzinga.com/25/05/45427302/anthony-scaramucci-forecasts-bitcoin-will-be-deemed-asset-class-akin-to-gold-when-it-reaches-500000">Anthony Scaramucci Says Once Bitcoin Hits $500,000 It Will Be Considered An Asset Class Just Like Gold</a> 
However, things started to change after BTC surpassed the $60,000 mark. Woo noticed a shift in the market, with the market beginning to heavily rely on derivatives, which were not being adequately represented by on-chain signaling.
The result-the letter which launched with a reliability of 83%, saw its reliability dip below 60%.
&#8220;When reliability dropped below 60%,&nbsp;I felt it was doing&nbsp;more harm than good, so&nbsp;I killer the letter. It&nbsp;was no longer suitable for&nbsp;its mission,&#8221; Woo said. &#8220;It was encouraging&nbsp;retail to play timing games&nbsp;and without disciplined risk management&nbsp;plebs were effectively gambling.&#8221;
Woo&#8217;s decision underscores the volatility and unpredictability of the Bitcoin market. 
Benzinga&#8217;s Take: While on-chain fundamentals often focus on measuring the intrinsic value of a cryptocurrency using data derived directly from the blockchain, derivatives could help traders hedge against price movements, protecting positions while boosting stability and liquidity. A comprehensive analysis should involve informed understanding of both these sets of metrics.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://benzinga.com/markets/cryptocurrency/25/05/45486583/michael-saylors-tip-to-grow-wealth-by-100x-dont-quit-jobs-invest-in-bitcoin-over-obscenely" target="_blank" rel="noreferrer noopener">Michael Saylor Has A Tip For Average People Looking To Grow Their Wealth By 100x, But He Doesn&#8217;t Want You To Quit Your Job To Invest In Bitcoin</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.<a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" rel="noreferrer noopener" target="_blank"></a>
Photo Courtesy: Wirestock Creators on Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Top Bitcoin Analyst Reveals Why They Shut Down Their Business That Was Making 'Millions Per Year'

FRSX

Trading Halt: Halted at 3:58:28 a.m. ET - Trading Halt: Halt News Pending

RKLB

Reported Saturday, Rocket Lab Completes Third Mission For iQPS With 100% Success In 2025, Next Launch Scheduled for June

Palmer Luckey says the arms race is no longer about bigger missiles but autonomous weapons that operate using artificial intelligence and he wants the United States to be "the world gun store" that supplies them.
What Happened: The Anduril founder <a href="https://www.cbsnews.com/news/palmer-luckey-ai-powered-autonomous-weapons-future-of-warfare-60-minutes-transcript/">told</a> CBS' 60 Minutes that commercial tech has surpassed the Pentagon, arguing that a Tesla has better AI than any U.S. aircraft and a Roomba has better autonomy than most Pentagon weapons systems.
"Right now, there are so many weapon systems that require manning… If I can have one guy command and controlling 100 aircraft, that's a lot easier," Luckey said.
Though he conceded the idea of autonomous weapons "is a scary idea," he insisted, "that's the world we live in." He added, "There's no moral high ground to making a land mine that can't tell the difference between a school bus full of children and Russian armor."
See also: <a href="https://www.benzinga.com/25/05/45487522/tesla-is-accepting-trade-ins-for-2024-cybertruck-amid-plummeting-sales-figures-report">Tesla Is Accepting Trade-Ins For 2024 Cybertruck Amid Plummeting Sales: Report</a>
Luckey says the Costa Mesa, California, company will top $6 billion in <a href="https://www.benzinga.com/news/24/08/40280155/lockheed-martin-boeing-and-northrop-grumman-rival-anduril-led-by-peter-thiels-venture-capital-raises">defense contracts</a> by year-end after beating legacy primes for Air Force and Special Operations deals. "We're gonna be making large numbers of cruise missiles, large numbers of fighter jets… day 100," he told CBS.
U.N. Secretary-General António Guterres has labeled fully autonomous lethal weapons "politically unacceptable and morally repugnant" and <a href="https://press.un.org/en/2025/sgsm22643.doc.htm">wants a treaty</a> banning them by 2026. Luckey counters: "It's not a question between smart weapons and no weapons. It's a question between smart weapons and dumb weapons."
The 32-year-old sold Oculus to Facebook for $2 billion in 2014 and was <a href="https://www.benzinga.com/news/24/10/41269578/mark-zuckerbergs-meta-and-oculus-founder-palmer-luckey-mend-fences-the-people-responsible-arent-even">fired two years later</a> after a $9,000 political donation sparked controversy — an ouster that <a href="https://www.benzinga.com/news/24/04/38246351/meta-cto-gets-called-out-by-founder-of-company-building-electronic-border-wall-you-arent-credible">Facebook denies</a>.
Photo Courtesy: Anggalih Prasetya On Shutterstock.com
Read next: <a href="https://www.benzinga.com/25/05/45487650/nvidia-tsmc-and-apple-supplier-foxconn-partner-to-develop-taiwan-ai-supercomputer">Nvidia, TSMC And Apple Supplier Foxconn Partner To Develop Taiwan AI Supercomputer</a>

Emerging Markets

America Must Shift Roles From 'World Police' To 'World Gun Store,' Says Palmer Luckey

– Analysis Presented at the Heart Failure 2025 Congress Supports Primary Findings, Highlighting Impact of AMVUTTRA, which Delivers Rapid Knockdown of Transthyretin –
– Additional 42-Month Data Reinforce Vutrisiran's Impact on the Risk of All-Cause Mortality and Further Underscore the Effect on Cardiovascular Mortality –
– Vutrisiran Demonstrated Substantial Benefit Across a Range of Cardiovascular Events, Notably Reducing Urgent Heart Failure Visits by 46% in the Overall Patient Population During the Double-Blind Period –
– Findings Simultaneously Published in JACC –
– Details of TRITON-CM Phase 3 Study Evaluating Alnylam's Investigational Next-Generation TTR Silencer, Nucresiran, to be Presented at Congress –

ALNY

Reported Saturday, Alnylam's Vutrisiran Reduces All-Cause And Cardiovascular Mortality By Over 30% In ATTR-CM Patients, New 42-Month HELIOS-B Data Show

After Donald Trump signed an <a href="https://www.benzinga.com/general/health-care/25/05/45384935/trump-again-promises-lower-drug-prices-by-cutting-out-middlemen-like-unitedhealth-cvs-will-it-work-this-time">executive order</a> slashing drug prices last week, experts have highlighted how pharmacy benefit managers (PBMs) could be hit the hardest despite pharmaceutical companies facing the potential of compressed margins amid poor pricing power.
What Happened: According to Thomas Shipp, the head of equity research at LPL Financial, the pressure that the <a href="https://www.benzinga.com/news/25/05/45389750/trump-claims-drug-price-crackdown-could-slash-your-prescription-costs-by-59-but-will-big-pharma-fight-it-again">pharmaceutical manufacturers</a> are facing to lower prices domestically, &#8220;has the potential to compress margins by eroding pricing power and would provide a significant headwind to drug manufacturer share prices.&#8221;
However, he explains that the &#8220;middlemen&#8221; or PBMs that facilitate drug distribution and negotiate with pharmaceutical drug manufacturers to lower prescription costs have come under scrutiny for opaque pricing practices, like retaining rebates from drug manufacturers and "spread pricing."
&#8220;PBMs pay pharmacies less than what they charge health plan participants for drugs,&#8221; he said.
Another April 15 <a href="https://www.benzinga.com/markets/25/04/44866755/mark-cuban-says-this-trump-healthcare-order-could-save-hundreds-of-billions">executive order</a> signed by Trump called for increased transparency into PBM fees and requested that the role of these middlemen be reevaluated.
CVS Caremark, owned by CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), Express Scripts, owned by Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), and OptumRx, owned by UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), are the biggest PBM companies.
Shipp also underscored that PBM savings are expected, but direct price controls pose a longer-term risk for U.S.-heavy drugmakers. Transparency will reveal if PBM margin erosion can prevent deeper manufacturer cuts, he highlights.
&#8220;While many questions remain about how these executive orders will be implemented, after the initial news flow is digested, the net effect appears less detrimental to pharmaceutical drug manufacturers than to PBMs,&#8221; said Shipp.
&#8220;That said, reworking the way Americans buy their medicine is going to take a long time. Along the way, efforts to support direct-to-consumer sales will support both the manufacturers leading the charge and those they partner with for distribution,&#8221; he added.
See Also: <a href="https://www.benzinga.com/general/market-summary/25/05/45465955/ark-invest-takes-swipe-at-mstr-mara-says-bitcoin-treasury-companies-dont-make-sense-fundin">Ark Invest Expert Takes Swipe At MSTR, MARA, Says &#8216;Bitcoin Treasury Companies Don&#8217;t Make Sense:&#8217; &#8216;Funding Purchases With Debt&#8230;Seems Like A Recipe For Disaster&#8217;</a>
Why It Matters: Meanwhile, the billionaire investor and Shark Tank fame, Mark Cuban, called PBMs a &#8220;racket&#8221; in an X post by explaining that they <a href="https://www.benzinga.com/personal-finance/25/04/44674382/mark-cuban-says-big-insurance-companies-and-pbms-control-healthcare-costs-everyone-has-to-kiss-their-a-and-accept-the-complications">negotiate rebates and not prices</a>.
&#8220;They negotiate rebates. Not prices. In fact, the big PBMs control more than 95pct of the rebate negotiations. Big brand Pharma companies can&#8217;t negotiate with anyone else. IMO, it&#8217;s a racket,&#8221; he said.
While the April 15 order calls for transparency in pricing, Cuban highlights that 30% of the $4.9 trillion in healthcare spending is attributed to the overhead insurance companies and pricing distortions big PBMs create.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">One of the great lies the big PBM industry tells us is that they are needed to negotiate lower prices. It&#39;s a lie. They negotiate rebates. Not prices. In fact, the big PBMs control more than 95pct of the rebate negotiations. Big brand Pharma companies can&#39;t negotiate with…
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1923880717420986860?ref_src=twsrc%5Etfw">May 17, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Here are the aforementioned PBMs operating companies that have performed in 2025.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Stocks</td>
<td>YTD Performance</td>
<td>One-Year Performance</td>
</tr>
<tr>
<td>CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</td>
<td>41.41%</td>
<td>8.94%</td>
</tr>
<tr>
<td>Cigna Group. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>)</td>
<td>16.92%</td>
<td>-3.73%</td>
</tr>
<tr>
<td>UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</td>
<td>-42.14%</td>
<td>-43.56%</td>
</tr>
</tbody>
</table>
</figure>
Here are a few pharma-linked ETFs for investors to consider.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Pharma ETFs</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)</td>
<td>-0.28%</td>
<td>-4.66%</td>
</tr>
<tr>
<td>iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td>-1.20%</td>
<td>-2.03%</td>
</tr>
<tr>
<td>Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>)</td>
<td>-3.45%</td>
<td>-0.83%</td>
</tr>
<tr>
<td>SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)</td>
<td>-4.83%</td>
<td>-1.70%</td>
</tr>
<tr>
<td>KraneShares MSCI All China Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KURE#NYSE">KURE</a>)</td>
<td>11.10%</td>
<td>1.65%</td>
</tr>
<tr>
<td>First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>)</td>
<td>-6.51%</td>
<td>-6.89%</td>
</tr>
<tr>
<td>Direxion Daily Pharmaceutical &amp; Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PILL#NYSE">PILL</a>)</td>
<td>-23.63%</td>
<td>-24.07%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, ended higher on Friday. The SPY was up 0.63% to $594.20, while the QQQ advanced 0.44% to $521.51, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45433051/jim-cramer-says-gulf-countries-will-become-the-largest-hyperscalers-in-the-world-following-ai-deals">Jim Cramer Says Gulf Countries Will Become &#8216;Largest Hyperscalers In The World&#8217; After Nvidia&#8217;s 18,000 Blackwell Chip Deal</a></li>
</ul>
Photo courtesy: Rawpixel.com / Shutterstock.com

Health Care

FTXH

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion

As part of "Choose France," <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4430320-1&amp;h=1445138467&amp;u=https%3A%2F%2Fwww.kyndryl.com%2Ffr%2Ffr&amp;a=Kyndryl">Kyndryl</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KD#NYSE">KD</a>), a leading provider of mission-critical enterprise technology services, announced that it will invest up to €100 million over three years in France to strengthen the country's capabilities in data, artificial intelligence (AI) and cyber resilience.
&nbsp;
"I welcome the decision by Kyndryl, a leading player in enterprise technology services, in the expansion of their activities in France. This investment reflects the strength of our ecosystem, and the confidence France inspires when it comes to supporting ambitious technology projects. This initiative, facilitated by the teams of Business France, further reinforces our position as a leading innovation hub — built on world-class talent, a clear vision, and a stable, forward-looking environment," said Marie-Cécile Tardieu, Chief Operating Officer of Business France.

Kyndryl to Invest €100M in France to Boost AI, Data, and Cybersecurity Capabilities

<ul>
<li>Data suggests that single dose of RJVA-001 leads to durable metabolic improvements with low systemic GLP-1 exposure in db/db mouse model of T2D— potentially simultaneously addressing durability, adherence, and tolerability challenges seen with current GLP-1 drugs</li>
<li>Endoscopic ultrasound-guided delivery achieves targeted pancreatic expression in a large animal model with no toxicity observed to date</li>
<li>Data show nutrient-responsive GLP-1 secretion in human beta cells and human islets, demonstrating that Rejuva mimics natural hormone regulation rather than constant drug-driven stimulation</li>
<li>Rejuva advancing toward first-in-human studies; first CTA module submission for RJVA-001 expected by June 2025</li>
</ul>

GUTS

Reported Saturday, Fractyl Health Showcases Preclinical Rejuva Data At ASGCT 2025 Demonstrating Durable Metabolic Benefits With Low Systemic GLP-1 Exposure

<ul>
<li>Data confirmed TX45's tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF")</li>
<li>In new echocardiographic analysis, TX45 treatment resulted in sustained hemodynamic effects for 29 days</li>
<li>TX45 improved cardiac and pulmonary hemodynamics in PH-HFpEF patients across a range of left ventricular ejection fractions ("LVEF"), including LVEF≥50% and LVEF 41-49%</li>
</ul>

TECX

Reported Saturday, Tectonic Therapeutic Presents Full Phase 1b Results For TX45 in PH-HFpEF Showing Sustained Hemodynamic Improvements And Strong Safety Profile

Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Taiwan Semiconductor Manufacturing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>), and Hon Hai Precision Industry Co., better known as Foxconn, announced on Sunday a partnership to build an advanced artificial intelligence supercomputer in Taiwan.
What Happened: The collaboration includes Foxconn&#8217;s subsidiary Big Innovation Co. delivering a supercomputer equipped with 10,000 NVIDIA Blackwell GPUs, representing one of Asia&#8217;s most powerful AI computing infrastructures to date.
&#8220;AI has ignited a new industrial revolution — science and industry will be transformed,&#8221; said Jensen Huang, founder and CEO of NVIDIA, at the COMPUTEX technology conference.
The Taiwan National Science and Technology Council will invest in the supercomputer to provide AI cloud computing resources across Taiwan&#8217;s technology ecosystem. Officials aim to create &#8220;an AI-focused industrial ecosystem in southern Taiwan,&#8221; according to Minister Wu Cheng-Wen.
TSMC, the world&#8217;s largest contract chipmaker, plans to utilize the system to accelerate semiconductor research and development. &#8220;By harnessing advanced AI infrastructure, we empower our researchers to accelerate breakthroughs in semiconductor technology,&#8221; said C.C. Wei, chairman and CEO of TSMC.
See Also: <a href="https://www.benzinga.com/25/05/45486985/peter-schiff-slams-trumps-tariff-logic-higher-prices-are-necessary-to-shrink-trade-deficit">Peter Schiff Slams Trump&#8217;s &#8216;Eat The Tariffs&#8217; Message To Walmart: He Might As Well Ask It To Eat &#8216;Rent, Wages, Insurance…&#8217;</a>
Why It Matters: The system will feature NVIDIA Blackwell Ultra systems, including the NVIDIA GB300 NVL72 rack-scale solution with specialized networking technologies. Big Innovation Cloud will also participate in the NVIDIA DGX Cloud Lepton marketplace, providing enterprises and research institutions access to advanced GPU resources.
This partnership expands on Nvidia&#8217;s recent global AI initiatives, including planned investments of $500 billion in U.S. AI infrastructure. The <a href="https://www.benzinga.com/markets/equities/25/05/45398595/trump-praises-nvidia-ceo-jensen-huang-at-saudi-summit-tim-cook-isnt-here-but-you-are-controlling-99-of-the-chip-market-thats-not-easy-to-beat">company has seen significant market growth</a>, recently re-entering the $3 trillion market capitalization category amid surging demand for AI chips worldwide.
Foxconn plans to apply the supercomputer&#8217;s capabilities across three core areas: smart cities, electric vehicles, and manufacturing, enhancing Taiwan&#8217;s technological competitiveness in the rapidly evolving AI landscape.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45486943/arthur-hayes-forecasts-bitcoin-will-hit-200000-in-next-bull-run-anticipates-revival-of-fortunes-for-this-hated-coin">Arthur Hayes Forecasts Bitcoin Will Hit $200,000 In Next Bull Run, Anticipates Revival Of Fortunes For This &#8216;Hated&#8217; Coin</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo: epha1st0s/Shutterstock

Tech

NVDA

Nvidia, TSMC And Apple Supplier Foxconn Partner To Develop Taiwan AI Supercomputer

Reported Sunday, Fiserv Unveils Clover Hospitality By BentoBox To Transform Premium Dining With Smart POS, Checkless Payments, And Guest-Centric Tools

<ul>
<li>Deep, durable and consistent reductions in TTR were sustained at two years, following a one-time dose of nex-z</li>
<li>Clinically meaningful improvements in ATTRv-PN related outcomes observed at 24 months compared to baseline, including in patients who were previously progressing on patisiran</li>
<li>Continue to observe generally favorable safety and tolerability data in the full Phase 1 cohort with no new drug-related adverse events within the follow-up period</li>
<li>Enrollment continues to progress well in MAGNITUDE-2, which is designed to measure clinical outcomes (including mNIS+7) and evaluate how a single dose of nex-z can lead to reduction in serum TTR, to potentially support a BLA submission by 2028</li>
</ul>

NTLA

Reported Sunday, Intellia Reports 2-Year Phase 1 Data For Nexiguran Ziclumeran In ATTRv-PN Showing Deep, Durable TTR Reduction And Functional Improvements

The CNN Money Fear and Greed index showed an improvement in the overall market sentiment, while the index remained in the &#8220;Greed&#8221; zone on Friday.
U.S. stocks settled higher on Friday, with the S&amp;P 500 recording gains for the fifth straight session and also notching weekly gains. For the week, the S&amp;P 500 gained 5.3%, while the Dow added 3.4%. The Nasdaq Composite was the standout performer, surging 7.2% last week.
Tech stocks also recorded strong gains last week, with shares of Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) jumping around 16% and Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) gaining 8%. Shares of Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), meanwhile, gained around 6% last week.
On the economic data front, the University of Michigan consumer sentiment for the US dipped to 50.8 in May compared to April&#8217;s reading of 52.2 and down from market estimates of 53.4. U.S. import prices rose by 0.1% month-over-month in April compared to a revised 0.4% decline in the previous month. U.S. export prices increased 0.1% month-over-month in April, versus market estimates of a 0.5% fall.
Most sectors on the S&amp;P 500 closed on a positive note, with health care, utilities, and real estate stocks recording the biggest gains on Friday. However, energy stocks bucked the overall market trend, closing the session lower.
The Dow Jones closed higher by around 332 points to 42,654.74 on Friday. The S&amp;P 500 gained 0.70% to 5,958.38, while the Nasdaq Composite jumped 0.52% to 19,211.10 during Friday's session.
Investors are awaiting earnings results from Global Ship Lease Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSL#NYSE">GSL</a>), ZIM Integrated Shipping Services Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>), and Trip.com Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>) today.
At a current reading of 70.6, the index remained in the &#8220;Greed&#8221; zone on Friday, versus a prior reading of 69.2.
What is CNN Business Fear &amp; Greed Index?
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/05/45466164/jim-cramer-prefers-autozone-over-rival-buy-the-one-thats-not-going-to-stock-split">Jim Cramer Prefers AutoZone Over Rival: &#8216;Buy The One That&#8217;s Not Going To Stock Split&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

AAPL

TCOM

S&P 500 Gains For Fifth Session: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is reportedly accepting trade-ins for the Cybertruck, a year after Elon Musk&#8217;s company launched the pickup truck.
What Happened: Tesla is offering owners of the Cybertruck Foundation Series a chance to trade in their vehicle for an upgrade, Electrek reported <a href="https://electrek.co/2025/05/18/tesla-starts-accepting-cybertruck-trade-ins-confirms-insane-depreciation/">on</a> Sunday.
The report outlines that Tesla was offering $65,400 for an All-wheel-drive 2024 Cybertruck with 6,211 miles on the odometer. The AWD trim of the Cybertruck retailed for over $100,000 at launch.
The trade-in value offered by Tesla represents more than 34% decline in value in a year, much higher than the 20% depreciation generally expected for pickup trucks during the same period, the report suggests.
Why It Matters: The news comes in as the EV giant is experiencing difficulties in getting Cybertruck units off the dealership lots, with the brand reportedly sitting on <a href="https://www.benzinga.com/markets/25/05/45216453/tesla-has-over-10000-units-of-unsold-cybertrucks-in-its-us-inventory-amid-poor-sales-report">over 10,000 unsold units</a> of the pickup truck.
This is despite offering <a href="https://www.benzinga.com/markets/equities/25/04/44755221/tesla-unveils-new-cybertruck-long-range-trim-with-a-362-mile-range-and-reduced-features">a cheaper trim level </a>of the Cybertruck with increased range, but at the cost of some hauling and towing capacity as well as feature omissions.
Musk's company has also tried to make the Cybertruck more appealing to the conventional pickup truck buyer by pivoting the <a href="https://www.benzinga.com/25/04/44919745/tesla-shifts-cybertruck-marketing-strategy-to-appeal-to-traditional-pick-up-truck-customers-amid-poor-sales">product's marketing strategy</a> to position it as a lifestyle vehicle for the "working man."
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="200" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19020801/TSLA-19-MAY-2025-1024x200.jpg" alt="" class="wp-image-919245" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19020801/TSLA-19-MAY-2025-1024x200.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19020801/TSLA-19-MAY-2025-300x59.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19020801/TSLA-19-MAY-2025-768x150.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19020801/TSLA-19-MAY-2025-1536x300.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19020801/TSLA-19-MAY-2025.jpg 1641w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
TSLA stock offers excellent Momentum and Quality and has a satisfactory Growth rating, but scores poorly on the Value metric. For more such insights, sign up for<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"> Benzinga Edge</a> today!
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/tech/25/05/45483858/elon-musk-asked-his-date-do-you-ever-think-about-electric-cars-the-date-flopped-but-his-obsession-sparked-a-400-billion-journey">Elon Musk Asked His Date, &#8216;Do You Ever Think About Electric Cars?&#8217; — The Date Flopped, But His Obsession Sparked A $400 Billion Journey</a></li>
</ul>
Photo courtesy: Jonathan Weiss / Shutterstock.com

TSLA

Tesla Is Accepting Trade-Ins For 2024 Cybertruck Amid Plummeting Sales: Report

Billionaire hedge-fund veteran Stanley Druckenmiller says the mark of every "great investor" is the willingness to make one outsized, high-conviction bet and then guard it like a hawk.
What Happened: "The mistake I'd say 98 percent of money managers and individuals make is they feel like they've got to be playing with a bunch of stuff," Druckenmiller <a href="https://gallery.mailchimp.com/6750faf5c6091bc898da154ff/files/Druck.pdf?utm_source=PAID+The+Idea+Farm&amp;utm_campaign=def2702a2a-First_Email8_14_2012&amp;utm_medium=email&amp;utm_term=0_ac58d173d8-def2702a2a-411831749">told</a> members of Palm Beach's Lost Tree Club in 2015. "If you really see it, put all your eggs in one basket and watch the basket very carefully," he added, invoking a well-known quote.
In a 2021 Q&amp;A <a href="https://thehustle.co/stanley-druckenmiller-q-and-a-trung-phanin">with</a> The Hustle, he doubled down: "When I've looked at all the investors (that) have very large reputations—Warren Buffett, Carl Icahn, George Soros — they all only have one thing in common… make large concentrated bets where they have a lot of conviction."
See also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45486943/arthur-hayes-forecasts-bitcoin-will-hit-200000-in-next-bull-run-anticipates-revival-of-fortunes-for-this-hated-coin">Arthur Hayes Forecasts Bitcoin Will Hit $200,000 In Next Bull Run, Anticipates Revival Of Fortunes For This &#8216;Hated&#8217; Coin</a>
"In my thinking, [concentrating your bets] decreases your overall risk because… If you have a big, massive position, it has your attention," Druckenmiller told The Hustle, closing with, "My favorite quote of all time is maybe Mark Twain: ‘Put all your eggs in one basket and watch the basket carefully.' I tend to think that's what great investors do."
Backing It Up: Druckenmiller pointed to Icahn's move to <a href="https://www.benzinga.com/news/14/01/4246808/carl-icahn-buys-more-apple-shares-after-saying-he-would-be-better-off-if-apple-di">plow about $3 billion</a> into Apple a decade ago, calling it textbook conviction investing. He also recalled Soros urging him to short 200 percent of the Quantum Fund against the pound on Black Wednesday, a wager that <a href="https://www.benzinga.com/general/24/03/37534248/a-british-pounding-how-george-soros-made-over-1-billion-betting-against-the-bank-of-england">pocketed $1 billion</a> in a day.
The veteran speaks from experience. His Duquesne Family Office has averaged <a href="https://www.benzinga.com/news/24/05/38686502/hedge-fund-legend-druckenmiller-shares-his-top-secrets-for-30-returns">30 percent annual returns</a> and helped build a fortune near $10 billion, according to Benzinga tallies. His focus also echoes <a href="https://www.benzinga.com/general/24/01/36800431/warren-buffetts-first-failed-business-venture-cost-him-20-of-his-net-worth-now-he-says-risk-comes-fr">Buffett's warning</a> that "risk comes from not knowing what you're doing," a line Buffett often deploys to defend his own concentrated portfolio.
Photo Courtesy: Reza Maftazani On Shutterstock.com
Read next: <a href="https://www.benzinga.com/25/05/45486985/peter-schiff-slams-trumps-tariff-logic-higher-prices-are-necessary-to-shrink-trade-deficit">Peter Schiff Slams Trump&#8217;s &#8216;Eat The Tariffs&#8217; Message To Walmart: He Might As Well Ask It To Eat &#8216;Rent, Wages, Insurance…&#8217;</a>

Equities

Success Stories

Stanley Druckenmiller's Contrarian Investment Philosophy Helped Make Him A Billionaire: 'Put All Your Eggs In One Basket…'

President Donald Trump initiated separate phone calls Monday with Russian President Vladimir Putin and Ukrainian President Volodymyr Zelenskyy in a bid to broker a ceasefire in the Ukraine war.
What Happened: Trump expressed hopes for a &#8220;productive day&#8221; in a weekend social media post, indicating his first call would be with Putin at 10 a.m. Monday to discuss ending what he termed the &#8220;bloodbath&#8221; of a war that &#8220;should have never happened,&#8221; <a href="https://apnews.com/article/trump-putin-zelenskyy-russia-ukraine-war-ceasefire-3ec4144fecac5d77c8bb33cc4d7018ce">according</a> to the Associated Press. 
The calls represent a crucial test of Trump&#8217;s dealmaking reputation after claiming he could quickly resolve the conflict that began with Russia&#8217;s invasion in February 2022.
Treasury Secretary Scott Bessent warned Sunday on NBC&#8217;s &#8220;Meet the Press&#8221; that failure by Putin to negotiate &#8220;in good faith&#8221; could trigger additional sanctions against Russia. Bessent suggested former President Joe Biden-era sanctions were insufficient because they preserved Russia&#8217;s oil revenues to prevent U.S. price increases.
The diplomatic push comes amid escalating violence, with the Kremlin launching its largest drone barrage against Ukraine since the invasion began — 273 exploding drones and decoys targeting Kyiv, Dnipropetrovsk and Donetsk regions.
Zelenskyy, who met with Vice President JD Vance and Secretary of State Marco Rubio in Rome on Sunday, has insisted on an &#8220;unconditional ceasefire&#8221; before any negotiations. Putin recently rejected Zelenskyy&#8217;s offer to meet in Turkey, though both countries committed to exchanging 1,000 prisoners of war each.
See Also: <a href="https://www.benzinga.com/news/management/25/05/45486759/dairy-queen-ceo-reveals-warren-buffetts-shocking-first-move-in-job-interview-ill-never-forget-the-day">Dairy Queen CEO Reveals Warren Buffett&#8217;s Shocking First Move in Job Interview: &#8216;I&#8217;ll Never Forget The Day…&#8217;</a>
Why It Matters: Former U.S. Ambassador to Ukraine Bridget Brink, who resigned last month, expressed concern about Trump&#8217;s approach, stating, &#8220;Peace at any price is not peace at all. It&#8217;s appeasement.&#8221;
The outcome of these diplomatic efforts could significantly impact market stability, particularly if new sanctions target Russia&#8217;s energy sector, potentially disrupting global oil supplies and prices.
Meanwhile, Ukraine and the U.S. have revived discussions on a <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44889511/trump-may-take-a-pass-on-russia-ukraine-peace-talks-without-progress">joint investment fund for post-war reconstruction</a>, signaling potential future opportunities for investors in Ukrainian energy infrastructure and mineral resources.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45486728/elon-musks-mother-shares-1989-aptitude-test-results-revealing-highest-engineering-aptitude-score-of-tesla-ceo-at-age-17">Elon Musk&#8217;s Mother Shares 1989 Aptitude Test Results Revealing &#8216;Highest Engineering Aptitude&#8217; Score Of Tesla CEO At Age 17</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock

Global

General

Trump Pushes For Russia-Ukraine Ceasefire To End 'Bloodbath' In High-Stakes Calls With Russian President And Zelenskyy Amid Drone Attacks

<ul>
<li>&nbsp;Slowing of progression of disease observed via MRI at 24 months</li>
<li>Improvements in outcomes and reduction in sorbitol maintained through 24 months</li>
<li>Statistically significant correlation between absolute reduction in sorbitol and change in 10MWRT and CMT-FOM Lower Limb domain at 12 months, though the primary endpoint of 10MWRT at 12 months was not statistically significant (the measure has since been removed from the CMT-FOM clinical outcomes assessment based upon the results of the ACT-CMT study&#x2A;)</li>
<li>Statistically significant improvement in CMT-HI and statistically significant correlation between percent change in sorbitol and change in CMT-HI at 12 months</li>
<li>Treatment with govorestat in CMT-SORD-Null rats demonstrated a highly statistically significant 37% (p=0.005) reduction of sorbitol in the sciatic nerve, the tissue of interest, after treatment with govorestat. Reflective of the&nbsp;peripheral neuropathy experienced by patients with CMT-SORD.</li>
<li>Govorestat remains generally safe and well tolerated</li>
<li>Company remains committed to the potential NDA submission of govorestat for treatment of CMT-SORD in 2025</li>
</ul>

APLT

Reported Sunday, Applied Therapeutics Reports 24-Month Data From INSPIRE Trial Showing Govorestat Slows Disease Progression In CMT-SORD, Reinforces Plans For 2025 NDA

Nvidia Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) has decided not to launch a new chip from its Hopper series in China. This decision comes in the wake of U.S. government restrictions on H20 chip sales, as confirmed by Nvidia&#8217;s CEO, Jensen Huang.
What Happened: Huang, during a livestream by Taiwan&#8217;s Formosa TV News network, stated that modifying the Hopper series further is not feasible, reported Reuters. Earlier this month, Reuters reported that Nvidia intends to launch a downgraded version of the H20 chip in China within two months. This strategy aims to increase sales in a market where Nvidia has lost ground to domestic competitors like Huawei.
&nbsp;&#8220;It&#8217;s not Hopper because it&#8217;s not possible to modify Hopper anymore,&#8221; confirmed Huang. 
After the U.S. imposed new restrictions on H20 chip exports to China, Huang visited the country. The H20 chip is the only AI chip that Nvidia can legally sell in China, a market that Huang has often highlighted as crucial to Nvidia&#8217;s growth.
The U.S. Framework for Artificial Intelligence Diffusion, released in January, sought to restrict AI chip exports to the majority of countries. Huang has previously criticized these export controls and called for the global expansion of U.S. technology.
SEE ALSO:&nbsp;<a href="https://benzinga.com/25/05/45486095/bitcoin-breaks-107000-ethereum-dips-dogecoin-rallies-as-greed-sentiment-takes-over-analyst-predicts-great-6-8-week-period" target="_blank" rel="noreferrer noopener">Bitcoin Breaks $107,000, Ethereum Dips, Dogecoin Rallies As &#8216;Greed&#8217; Sentiment Takes Over: Analyst Predicts BTC &#8216;Primed&#8217; For A New All-Time High &#8211; Grayscale Bitcoin Mini Trust (BTC) Common units of fra</a>
Why It Matters: China accounted for 13% of Nvidia&#8217;s total sales&nbsp;in the fiscal year ending&nbsp;January 26, generating&nbsp;$17 billion in revenue for&nbsp;the company. The decision not to launch the Hopper series chip could impact Nvidia&#8217;s market share and revenue in China.
Last week, Nvidia and other chip stocks <a href="https://www.benzinga.com/25/05/45417156/nvidia-amd-stocks-climb-as-trump-plans-to-ease-ai-chip-export-rules">gained after</a> reports indicated plans by the Trump Administration to repeal the Biden administration's artificial intelligence diffusion. This policy created three broad tiers of access for countries seeking AI chips and would have taken effect on May 15.
Meanwhile, Nvidia is <a href="https://www.benzinga.com/media/25/05/45460918/jensen-huang-led-nvidia-plans-new-shanghai-research-hub-to-stay-competitive-in-china-as-us-export-curbs-threaten-ai-chip-sales-report">planning to expand</a> its research footprint in China with a new Shanghai-based R&amp;D center. This move signals a strategic push to retain AI dominance in the region amid tightening U.S. export restrictions.
Benzinga Edge Stock Rankings shows that NVDA had a strong price trend over the short, medium and long term. Its momentum ranking was strong at the 84th percentile, whereas its value ranking was poor at the 7th percentile; the details of other metrics are <a href="https://www.benzinga.com/quote/NVDA">available here</a>.
Over the past month, Nvidia stock has surged over 39%.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/05/45485038/robert-kiyosaki-predicts-bitcoin-to-reach-250000-buy-more-do-not-sell" target="_blank" rel="noreferrer noopener">Robert Kiyosaki Predicts Bitcoin To Reach $250,000: &#8216;Buy More. Do Not Sell.&#8217; &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Nvidia Abandons Hopper Series Chip Release In China Due To US Restrictions: 'Not Possible To Modify Hopper Anymore'

<ul>
<li>&nbsp;Two New Analyses from SEQUOIA-HCM on Effect of Aficamten Between Patients with Mild and Moderate-to-Severe Symptoms, and Across Geographic Regions</li>
<li>HEOR Analyses of Real-World Data Reveal Disparities in Outcomes In Females and Older Patients with Non-Obstructive HCM</li>
</ul>

CYTK

Reported Sunday, Cytokinetics Presents New SEQUOIA-HCM Analyses at ESC Heart Failure 2025 Showing Consistent Aficamten Efficacy Across Symptom Severity And Regions

Press Releases

Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel

Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904

Legal

Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization

Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program

Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects

Conduit Pharmaceuticals Announces Leadership Changes

Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset

Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

Comments

Conduit Pharmaceuticals

Noticias

Últimas noticias sobre Conduit Pharmaceuticals (NASDAQ:CDT) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL